Haoyuan Chemexpress

Shanghai Haoyuan Chemexpress Co., Ltd. (Stock Code: 688131), established in 2006, is located in the Zhangjiang Biomedical Base in Shanghai. The company focuses on the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs. As a high-tech enterprise, it provides global pharmaceutical companies and research institutions with related products and technical services ranging from drug discovery to the scaled production of APIs and pharmaceutical intermediates. The company has been honored with several titles such as "Specialized, Refined, Unique, and Innovative Enterprise" of Shanghai, "Small Giant Enterprise" of Shanghai, "Shanghai Brand Cultivation Demonstration Enterprise," "Shanghai Patent Work Pilot Enterprise," and "Pudong New Area Enterprise R&D Institution." Haoyuan Chemexpress has deep roots in the biopharmaceutical field, consistently adhering to independent scientific and technological innovation and courageously tackling technical challenges. After years of technical accumulation and industry experience, the company has developed six core technology platforms, including a High Potency Active Pharmaceutical Ingredient (HPAPI) Development Platform, a Multi-Chiral Complex Drug Technology Platform, a Vitamin D Derivative API R&D Platform, a Specialty Targeted Drug Development Platform, a Solid-State Chemistry Research Technology Platform, and a Molecular Building Blocks and Tool Compound Library Incubation Platform. Its service scope covers therapeutic areas such as anti-tumor, antiviral, diabetes, cardiovascular and cerebrovascular diseases, immune system, and nervous system treatments.To enhance innovation efficiency, the company continuously invests heavily in hardware facilities and equipment, equipping itself with advanced research and production facilities. It has built a kilogram-level GMP-condition laboratory and a pharmaceutical R&D center, establishing business centers in Hong Kong and the United States. The company firmly believes that talent drives innovation and places great emphasis on talent team building. Its core technical team possesses high technical expertise, strong innovation capabilities, and rich practical experience, having applied for over a hundred patents.